Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-986504 Monotherapy in Advanced or Metastatic NSCLC with Homozygous MTAP Deletion
jRCT2021250039Phase 2Suspended
- Sponsor
- Bristol Myers Squibb
- Start
- Jan 2025
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, open-label trial of MRTX1719 in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Objective Response Rate. Started Jan 2025; status: suspended.
02
Drugs
MRTX1719
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2021250039.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2021250039.